Beyond Air Inc

Beyond Air reported revenue of $1.77 million for Q1 2027, missing the Wall Street estimate of $2.21 million, after which the stock fell 7.11% in premarket trading. The company recorded a positive gross profit for the third consecutive quarter and improved its gross margin to 13%, while R&D expenses declined. Beyond Air confirmed its 2026 target of $8 million and its 2027 outlook of $16–18 million, is pinning hopes on the FDA decision for the second generation of LungFit PH, and has gained financial flexibility from fresh financing. Risks remain: ongoing net losses, revenue volatility, and dependence on the FDA approval timeline. » More on de.investing.com

Beyond Air asks shareholders to decide on a stock consolidation before the extraordinary general meeting on June 18 to raise the share price above Nasdaq’s $1.00 minimum. Nasdaq informed the company that the share price fell below the minimum requirement for 30 trading days and a delisting is threatened. The board would be authorized to set a consolidation ratio between 1:2 and 1:20; the board and CEO unanimously recommend approval. Voting shareholders must vote by June 17, otherwise the meeting may be adjourned. » More on de.investing.com

An independent review in Intensive Care Medicine Experimental summarizes 27 studies on the use of high‑dose (over 20 ppm) inhaled nitric oxide as an antimicrobial therapy for respiratory infections and outlines research areas such as nosocomial and ventilator-associated pneumonia, tuberculosis, and treatment of immunocompromised patients. Beyond Air comments on the publication and emphasizes that its LungFit system generates nitric oxide from ambient air and can deliver concentrations of 1–80 ppm. The company, which is commercializing the device, has FDA clearance and a CE mark for LungFit PH, reports $6.92 million in revenue in the last twelve months (growth 129%), and continues to run clinical trials for severe lung infections. » More on de.investing.com